Search Results
Results found for "Chris Evans"
- Bell-Evans model and steered molecular dynamics in uncovering the dissociation kinetics of ligands..
October 2022 Bell-Evans model and steered molecular dynamics in uncovering the dissociation kinetics optimized approach of combining the data derived from steered molecular dynamics simulations and the Bell-Evans
- Why Sokhom Pin Never Left GPCRs, Even When Everyone Else Did
But Sokhom Pin stayed loyal to GPCRs , even when big pharma turned its gaze to other targets like kinases
- The Imprecision Problem: Why Your GPCR Drug Discovery Program Is Off-Track Before It Even Starts
But here’s the reality: even ultra-specialized experts can’t fix systemic dysfunction in their spare Even flawless experiments collapse under sloppy systems. data management pipeline, teams waste hours cleaning, reconciling, and integrating before they can even
- Embark on a GPCR Adventure: Your Weekly Research Expedition! | Oct 21-27, 2024
Dimerization: Unveiling Its Role in Receptor Function and Signaling Sonja Peter , Brian Bender , Chris
- Sosei Heptares Confirms Senior Leadership Changes to Drive the Company Through the Next Stage ...
Chris Cargill appointed as President and Chief Executive Officer • Dr.
- Embark on a GPCR Adventure: Your Weekly Research Expedition! | Oct 21-27, 2024
Dimerization: Unveiling Its Role in Receptor Function and Signaling Sonja Peter , Brian Bender , Chris
- 📰 GPCR Weekly News, October 9 to 15, 2023
success Sosei and PharmEnable extend neurological disease drugs hunt Sosei Heptares’ President & CEO Chris
- 📰 GPCR Weekly News
INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease Chris
- 📰 GPCR Weekly News, October 16 to 22, 2023
Topline Safety and Tolerability Data from Proof-of-Concept Studies Sosei Heptares’ President & CEO Chris
- 📰 GPCR Weekly News, February 13 to 19, 2023
From the scientist’s view: a conversation with … Chris Tate AI is dreaming up drugs that no one has ever
- Unlocking the Future of Medicine: Advancements in GPCR Research
This week's highlight includes congrats to Omolade Otun, Chris de Graaf, Cherine Bechara, et al. for
- Targeting GPCRs in the CNS: Advances in Drug Discovery Strategies
Source: Kim J, Choi C. 2018 Feb;98:222-232. doi: 10.1016/j.biopha.2017.12.056 Azam S, Haque ME, Jakaria M, Jo SH, Kim IS, Choi Cells. 2020 Feb 23;9(2):506. doi: 10.3390/cells9020506 Kim J, Choi C.
- Biased Agonism at the GLP-1 Receptor: A Pathway to Improved Therapeutic Outcomes
Cary, B.P., et al., New Insights into the Structure and Function of Class B1 GPCRs.
- Nanobodies: New Dimensions in GPCR Signaling Research
G., Choi, H. J., Fung, J. J., Pardon, E., Casarosa, P., Chae, P. S., Devree, B. T., Rosenbaum, D.
- From Student to Mentor: What Alessandro Nicoli Learned About Leading in Science
Antonella Di Pizio’s lab , there was almost nothing—no team, no culture, not even proper desks. responsibilities: from building computational models of GPCRs to guiding interns, master’s students, and even “I remember my first day—we were even sharing the desk.
- Fentanyl and Xylazine: Why Breathing Fails in Overdose
The combination is not merely additive; it’s synergistic, shrinking tidal volume even when breathing the two drugs, there was a potentiation of fentanyl’s effect on tidal volume—mice were bringing in even Even if the respiratory rate doesn’t appear drastically lower, those pauses send oxygen levels plummeting A patient might appear stable on an oxygen monitor, even as their breathing mechanics are deteriorating Catherine’s work matters: it shows in mechanistic detail how fentanyl and xylazine change what overdose even
- Why Biotech Fundraising Fails Due to Intellectual Property Gaps
. 👉 Many biotech fundraising efforts stall even with solid science and data. When it is fragmented, even promising science struggles to move the round forward. Even experienced founders underestimate how sensitive investors are to ownership details. That uncertainty increases perceived risk, even if the underlying science is compelling. Even if the risk is manageable, not addressing it makes the fundraising process harder.
- The Perils and Guardrails of Modifying Signalling Proteins in Bioassays
small molecules, lipids, receptor-activity modifying proteins, autoantibodies, membrane stretch, and even the strongest coupling partner Gαs (Figure 2A), and for the glucagon-like-peptide-1 receptor (GLP-1R) even van der Westhuizen ET, Valant C, Sexton PM, Christopoulos A. Manchanda Y, ElEid L, Oqua AI, Ramchunder Z, Choi J, Shchepinova MM, et al. Why even physicists still don't understand quantum theory 100 years on.
- Drug Discovery Pharmacology Principles That Turn Assays Into Real Medicines
When responses are scaled consistently, comparisons remain meaningful even if the absolute maximum is Even experienced biologists sometimes treat EC₅₀ as if it reflects ligand affinity. Kenakin reveals how scaled pharmacological metrics allow teams to interpret receptor signaling changes even Even potent inhibitors may fail simply because they never reach sufficient concentration in vivo . Even promising molecules collapse due to safety issues, pharmacokinetics, or unexpected biology.
- The Hidden Cost of Unclear Biotech Positioning
Business development conversations feel inconsistent, even when the company and the science have not Over time, this constant adjustment drains confidence and momentum, even when the science is strong. The same company sounds different depending on the meeting , even when the science and the strategy have instead of the core value 5️⃣ The CEO and scientific leadership describe the company differently , even Even rejection becomes useful, because it is based on clear criteria rather than confusion. ✅ A biotech
- From GPCR Data Chaos to Decisive Action
Is Your GPCR Program Slowing Down—Even With Good Data? You’re not alone. I call it the Lego Bucket Problem : You’ve got CRO output, internal assay data, maybe even some promising calendly.com/drgpcr/yamina-corner Or explore how we can work together: 👉 Yamina.org 🔑 Key Takeaways ✅ Even
- Misread the Curve, Misjudge the Drug: Rethinking Antagonism in GPCR Pharmacology
But if the antagonist binds tightly and dissociates slowly, the receptor remains blocked, even at high This mimics non-competitive behavior, even if the antagonist occupies the orthosteric site. Antagonist “hogs” the receptor, depressing the response, even if more agonist is added.
- Is Your Agonist Really “Working”—Or Are You Just Seeing What Your System Allows?
Through powerful analogies (think batteries and balance scales), Terry reveals why different tissues—and even
- Innovative Data-Driven Solutions: The pHSense Revolution
Even minor adjustments can compromise photophysical properties. constructed the platform, tested every variable—pKa, brightness, lifetime—and made decisions that few would even The assay is compatible with SNAP-tags, FLAG-tags, HA-tags, and even antibody fragments for native GPCRs
- Why Fundraising Mistakes Kill Strong Biotech Startups
. 👉 None of these moves looks fatal on their own, yet together they quietly weaken even strong biotech And under pressure, even strong teams begin to confuse movement with direction. 👉 In early-stage biotech Roles are added to demonstrate scale, even when the organization is not structurally ready to support Strategy continues to shape decisions even when external pressure rises. ✅ This is the point where biotech When fundraising leads and strategy reacts, even strong biotech startups slowly lose coherence. ✅ The
- From Lab Logic to Leadership: How Scientific Thinking Holds Back Biotech Operations
. 👉 Most founders don’t even realize they’re still running their company like an academic research group Startups demand something different: ✅ Clarity of direction even when the picture is incomplete. The transition between the two isn’t automatic, even for the most capable founders.
- How Early Strategic Decision Making Creates Alignment and Better Results
. 👉 In biotech, where cycles are long and feedback is slow, this gap becomes even more pronounced. Early decisions shape what the team optimizes for , even when no one explicitly states it. 3️⃣ What will where alignment becomes the invisible mechanism that turns intent into movement. 👉 Without alignment, even Over time, this friction compounds and erodes confidence, even when the underlying strategy is sound.
- Orthosteric vs. Allosteric Interactions: The Silent Decider of Safety and Success
Modulators Expand Your Toolkit Allosterics offer a broader range of effects—additive, synergistic, or even Unlike orthosterics, they can discriminate between agonists, pathways, and even durations of action. orthosteric vs allosteric behavior can derail dose selection, lead to false negatives in early screens, or even
- From Ox Liver to AI: How the History of Pharmacology Shapes Its Future
And yes, you'll even meet the man who turned failed experiments into a Nobel Prize-winning discovery
- Antibodies That Don’t Block, They Activate: A New Angle on Autoimmunity and GPCRs
system is not just used for detection, but for functional screening : add ligands, track modulation, and even






















